AU2012300841C1 - Novel crystal form - Google Patents

Novel crystal form Download PDF

Info

Publication number
AU2012300841C1
AU2012300841C1 AU2012300841A AU2012300841A AU2012300841C1 AU 2012300841 C1 AU2012300841 C1 AU 2012300841C1 AU 2012300841 A AU2012300841 A AU 2012300841A AU 2012300841 A AU2012300841 A AU 2012300841A AU 2012300841 C1 AU2012300841 C1 AU 2012300841C1
Authority
AU
Australia
Prior art keywords
rilapladib
crystalline
crystalline rilapladib
disease
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012300841A
Other languages
English (en)
Other versions
AU2012300841A1 (en
AU2012300841B2 (en
Inventor
Mei-Yin Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2012300841A1 publication Critical patent/AU2012300841A1/en
Application granted granted Critical
Publication of AU2012300841B2 publication Critical patent/AU2012300841B2/en
Priority to AU2016200492A priority Critical patent/AU2016200492B2/en
Publication of AU2012300841C1 publication Critical patent/AU2012300841C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Glass Compositions (AREA)
AU2012300841A 2011-09-01 2012-08-31 Novel crystal form Ceased AU2012300841C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016200492A AU2016200492B2 (en) 2011-09-01 2016-01-28 Novel crystal form

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530104P 2011-09-01 2011-09-01
US61/530,104 2011-09-01
PCT/EP2012/067027 WO2013030374A1 (en) 2011-09-01 2012-08-31 Novel crystal form

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016200492A Division AU2016200492B2 (en) 2011-09-01 2016-01-28 Novel crystal form

Publications (3)

Publication Number Publication Date
AU2012300841A1 AU2012300841A1 (en) 2014-03-13
AU2012300841B2 AU2012300841B2 (en) 2015-10-29
AU2012300841C1 true AU2012300841C1 (en) 2016-02-18

Family

ID=46829730

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012300841A Ceased AU2012300841C1 (en) 2011-09-01 2012-08-31 Novel crystal form
AU2016200492A Ceased AU2016200492B2 (en) 2011-09-01 2016-01-28 Novel crystal form

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016200492A Ceased AU2016200492B2 (en) 2011-09-01 2016-01-28 Novel crystal form

Country Status (34)

Country Link
US (3) US9227953B2 (cg-RX-API-DMAC10.html)
EP (1) EP2751094B1 (cg-RX-API-DMAC10.html)
JP (1) JP6199291B2 (cg-RX-API-DMAC10.html)
KR (2) KR20140056297A (cg-RX-API-DMAC10.html)
CN (1) CN103906744A (cg-RX-API-DMAC10.html)
AU (2) AU2012300841C1 (cg-RX-API-DMAC10.html)
BR (1) BR112014004251A2 (cg-RX-API-DMAC10.html)
CA (1) CA2847066C (cg-RX-API-DMAC10.html)
CL (1) CL2014000489A1 (cg-RX-API-DMAC10.html)
CO (1) CO6890102A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140098A (cg-RX-API-DMAC10.html)
CY (1) CY1120784T1 (cg-RX-API-DMAC10.html)
DK (1) DK2751094T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2014000042A (cg-RX-API-DMAC10.html)
EA (1) EA027972B1 (cg-RX-API-DMAC10.html)
ES (1) ES2686563T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20181375T1 (cg-RX-API-DMAC10.html)
HU (1) HUE041578T2 (cg-RX-API-DMAC10.html)
IL (1) IL230977A (cg-RX-API-DMAC10.html)
LT (1) LT2751094T (cg-RX-API-DMAC10.html)
MA (1) MA35362B1 (cg-RX-API-DMAC10.html)
MX (1) MX349243B (cg-RX-API-DMAC10.html)
MY (1) MY172885A (cg-RX-API-DMAC10.html)
PE (1) PE20141411A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014500382A1 (cg-RX-API-DMAC10.html)
PL (1) PL2751094T3 (cg-RX-API-DMAC10.html)
PT (1) PT2751094T (cg-RX-API-DMAC10.html)
RS (1) RS57644B1 (cg-RX-API-DMAC10.html)
SG (1) SG2014011886A (cg-RX-API-DMAC10.html)
SI (1) SI2751094T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201800455T1 (cg-RX-API-DMAC10.html)
UA (1) UA114607C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013030374A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201401176B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227953B2 (en) * 2011-09-01 2016-01-05 Glaxo Group Limited Crystal form
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
BR112022017437A2 (pt) * 2020-03-30 2022-10-18 Jiangsu Yahong Meditech Co Ltd Forma de cristal do pró-fármaco de nitroxolina, composição farmacêutica contendo o mesmo, e método de preparação e aplicação do mesmo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030904A1 (en) * 2000-10-10 2002-04-18 Smithkline Beecham P.L.C. Pyridinone derivatives for treatment of atherosclerosis

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993025190A1 (en) 1992-06-10 1993-12-23 Eastman Kodak Company Surface modified nsaid nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US7741020B2 (en) 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US9029383B2 (en) * 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
BRPI0721697A2 (pt) * 2007-05-11 2014-08-05 Univ Jefferson " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2008140450A1 (en) * 2007-05-11 2008-11-20 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
EP2619203A4 (en) 2010-09-20 2014-04-16 Glaxo Group Ltd TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF
WO2012075917A1 (en) 2010-12-06 2012-06-14 Glaxo Group Limited Compounds
US8637536B2 (en) 2010-12-06 2014-01-28 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
US9227953B2 (en) * 2011-09-01 2016-01-05 Glaxo Group Limited Crystal form
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030904A1 (en) * 2000-10-10 2002-04-18 Smithkline Beecham P.L.C. Pyridinone derivatives for treatment of atherosclerosis

Also Published As

Publication number Publication date
LT2751094T (lt) 2018-11-12
UA114607C2 (uk) 2017-07-10
PH12014500382A1 (en) 2021-07-12
AU2016200492A1 (en) 2016-02-18
US9682074B2 (en) 2017-06-20
AU2016200492B2 (en) 2017-04-20
MY172885A (en) 2019-12-13
US20160367544A1 (en) 2016-12-22
MX349243B (es) 2017-07-18
RS57644B1 (sr) 2018-11-30
CN103906744A (zh) 2014-07-02
MA35362B1 (fr) 2014-08-01
KR20140056297A (ko) 2014-05-09
JP6199291B2 (ja) 2017-09-20
WO2013030374A1 (en) 2013-03-07
US9694004B2 (en) 2017-07-04
ES2686563T3 (es) 2018-10-18
CY1120784T1 (el) 2019-12-11
US9227953B2 (en) 2016-01-05
AU2012300841A1 (en) 2014-03-13
HK1198534A1 (en) 2015-05-15
EP2751094A1 (en) 2014-07-09
CR20140098A (es) 2014-05-06
PE20141411A1 (es) 2014-10-29
BR112014004251A2 (pt) 2017-03-21
HRP20181375T1 (hr) 2018-10-19
KR20190075172A (ko) 2019-06-28
SI2751094T1 (sl) 2018-10-30
JP2014525428A (ja) 2014-09-29
IL230977A0 (en) 2014-03-31
ZA201401176B (en) 2015-12-23
US20140213613A1 (en) 2014-07-31
US20160075685A1 (en) 2016-03-17
SMT201800455T1 (it) 2018-11-09
EP2751094B1 (en) 2018-06-20
AU2012300841B2 (en) 2015-10-29
IL230977A (en) 2016-08-31
EA201490536A1 (ru) 2014-08-29
PL2751094T3 (pl) 2018-11-30
HUE041578T2 (hu) 2019-05-28
PT2751094T (pt) 2018-10-19
SG2014011886A (en) 2014-05-29
DOP2014000042A (es) 2014-08-31
MX2014002454A (es) 2014-04-10
CL2014000489A1 (es) 2014-08-01
CO6890102A2 (es) 2014-03-10
DK2751094T3 (en) 2018-08-20
CA2847066C (en) 2019-04-30
CA2847066A1 (en) 2013-03-07
EA027972B1 (ru) 2017-09-29
NZ621315A (en) 2016-06-24

Similar Documents

Publication Publication Date Title
JP2013520488A (ja) ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法
AU2011334928A1 (en) Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
US9694004B2 (en) Crystal form
CN117642396A (zh) αVβ6和αVβ1整联蛋白抑制剂及其用途
TWI820182B (zh) 四氫哌喃基胺基－吡咯并嘧啶酮化合物的固體形式
WO2012038963A1 (en) An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
CN109843880B (zh) 4-(2-((1r,2r)-2-羟基环己基氨基)苯并噻唑-6-基氧基)-n-甲基吡啶酰胺的晶型
NZ621315B2 (en) Novel crystal form of rilapladib
KR20140022851A (ko) 오타믹사반의 벤조산염
HK1198534B (en) Novel crystal form
WO2014081025A1 (ja) ３，４－ジフルオロ－２－（２－フルオロ－４－ヨード－フェニルアミノ）－n－（２－ヒドロキシ－エトキシ）－５－（３－オキソ－[１，２]オキサジナン－２－イルメチル）－ベンズアミドの新規結晶形
US20120059034A1 (en) Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
JP7736311B2 (ja) ピリミジノジアゼピン誘導体の結晶性形態
WO2010084515A2 (en) A process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof
KR20260003055A (ko) 에베나마이드의 결정형
JP2025540298A (ja) Ｈｄａｃ阻害剤およびその使用
CA2685761A1 (en) New solid forms of fxa inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 16 OCT 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 16 OCT 2015

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired